Timpani Capital Management Llc increased its stake in Merit Med Sys Inc Com (MMSI) by 11.16% based on its latest 2017Q4 regulatory filing with the SEC. Timpani Capital Management Llc bought 16,787 shares as the company’s stock rose 1.16% while stock markets declined. The institutional investor held 167,275 shares of the health care company at the end of 2017Q4, valued at $7.23 million, up from 150,488 at the end of the previous reported quarter. Timpani Capital Management Llc who had been investing in Merit Med Sys Inc Com for a number of months, seems to be bullish on the $2.73B market cap company. The stock increased 0.65% or $0.35 during the last trading session, reaching $54.05. About 272,141 shares traded. Merit Medical Systems, Inc. (NASDAQ:MMSI) has risen 52.36% since May 22, 2017 and is uptrending. It has outperformed by 40.81% the S&P500.

Artal Group Sa decreased its stake in Alnylam Pharmaceuticals Inc (Call) (ALNY) by 20% based on its latest 2017Q4 regulatory filing with the SEC. Artal Group Sa sold 50,000 shares as the company’s stock rose 5.82% while stock markets declined. The institutional investor held 200,000 shares of the health care company at the end of 2017Q4, valued at $25.41M, down from 250,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Alnylam Pharmaceuticals Inc (Call) for a number of months, seems to be less bullish one the $10.13 billion market cap company. The stock decreased 1.96% or $2.01 during the last trading session, reaching $100.8. About 585,742 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 22, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Among 9 analysts covering Merit Medical (NASDAQ:MMSI), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical had 26 analyst reports since October 23, 2015 according to SRatingsIntel. The rating was initiated by Needham on Thursday, April 19 with “Buy”. Canaccord Genuity maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) on Thursday, March 1 with “Buy” rating. Bank of America initiated the shares of MMSI in report on Thursday, July 20 with “Buy” rating. The company was maintained on Wednesday, February 28 by Piper Jaffray. As per Thursday, July 27, the company rating was maintained by Canaccord Genuity. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) earned “Buy” rating by Canaccord Genuity on Monday, September 4. On Tuesday, July 19 the stock rating was initiated by Canaccord Genuity with “Buy”. Canaccord Genuity maintained the shares of MMSI in report on Thursday, April 26 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $3700 target in Monday, July 10 report. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) earned “Buy” rating by Canaccord Genuity on Sunday, October 8.

Timpani Capital Management Llc, which manages about $202.98 million and $277.89 million US Long portfolio, decreased its stake in Old Dominion Fght Lines Inc Co (NASDAQ:ODFL) by 3,185 shares to 45,857 shares, valued at $6.03M in 2017Q4, according to the filing. It also reduced its holding in Installed Building Products In (NYSE:IBP) by 5,207 shares in the quarter, leaving it with 74,077 shares, and cut its stake in Alarmcom Holding Inc.

Since December 15, 2017, it had 0 insider buys, and 1 sale for $407,782 activity.

Since January 4, 2018, it had 0 insider buys, and 10 insider sales for $38.04 million activity. Ausiello Dennis A also sold $2.57 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, March 13. Another trade for 38,460 shares valued at $5.50M was sold by Greene Barry E. SHARP PHILIP A had sold 15,000 shares worth $1.94M. Another trade for 7,221 shares valued at $985,958 was made by Greenstreet Yvonne on Monday, March 26. Shares for $4.17M were sold by SCHIMMEL PAUL. Shares for $12.67M were sold by Vaishnaw Akshay on Wednesday, March 14.

Investors sentiment increased to 2.03 in 2017 Q4. Its up 1.11, from 0.92 in 2017Q3. It increased, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Qs Limited Company accumulated 2,408 shares or 0% of the stock. M&T Bank Corp owns 4,110 shares. Cap World stated it has 137,700 shares or 0% of all its holdings. Westpac Bk Corp has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Tobam has 111,554 shares for 0.61% of their portfolio. 2,692 were reported by Lpl Limited Liability Company. Tci Wealth holds 11 shares. Assetmark Incorporated holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 14 shares. Bailard Inc has invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Clarivest Asset Management Limited Liability Com owns 19,500 shares for 0.04% of their portfolio. 55,630 are owned by Proshare Advisors Limited Liability. Blackrock Incorporated holds 0.04% or 7.12M shares in its portfolio. Opus Point Prtnrs Mngmt holds 4.73% or 43,064 shares in its portfolio. Frontier Capital Mngmt owns 33,681 shares or 0.03% of their US portfolio. Point72 Asset Lp holds 88,886 shares.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. As per Thursday, August 10, the company rating was maintained by BMO Capital Markets. As per Friday, August 11, the company rating was maintained by Stifel Nicolaus. Leerink Swann maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, January 25 with “Market Perform” rating. Chardan Capital Markets maintained the stock with “Buy” rating in Monday, June 12 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Friday, September 22 by BMO Capital Markets. The rating was maintained by Needham on Wednesday, November 16 with “Buy”. The rating was maintained by Chardan Capital Markets with “Buy” on Thursday, October 6. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report. The firm has “Buy” rating given on Friday, October 23 by Jefferies. The stock has “Equal-Weight” rating by Barclays Capital on Thursday, October 6.

Artal Group Sa, which manages about $6.63B US Long portfolio, upped its stake in Incyte Corp (Call) (NASDAQ:INCY) by 100,000 shares to 250,000 shares, valued at $23.68 million in 2017Q4, according to the filing. It also increased its holding in Krystal Biotech Inc by 50,000 shares in the quarter, for a total of 150,000 shares, and has risen its stake in Accelerate Diagnostics Inc (NASDAQ:AXDX).

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “Ionis Pharmaceuticals Prepares for Launch” on May 09, 2018, also Streetinsider.com with their article: “Alnylam Pharma (ALNY) Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc02” published on April 23, 2018, Fool.com published: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” on May 17, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Globenewswire.com and their article: “Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology …” published on May 11, 2018 as well as Seekingalpha.com‘s news article titled: “Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation” with publication date: April 30, 2018.